Sponsor & Exhibitor Profiles
Ascendis Pharma
Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit www.ascendispharma.com to learn more.
Bruker Biospin GmbH
Bruker’s differentiated high-value life science research and diagnostics solutions enable scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.
Bruker’s portfolio of 3D X-ray microCT systems offers turnkey solutions for non-destructive, high resolution 3D imaging of small laboratory animals and a wide variety biological samples. This includes mineralized and soft tissues, tumors, plants and insects, as well as archeological and paleontological research fields.
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals is a Swiss-based pharmaceutical company focused on the late-stage development and commercialization of medications for niche endocrine, metabolic and musculoskeletal disorders. The flagship product of EffRx, Binosto® (buffered soluble alendronate), is a novel treatment for postmenopausal osteoporosis, offering enhanced convenience and tolerability. Binosto® is successfully commercialized through licensees in Europe, the United States, Asia and the Middle East. EffRx also directly markets a portfolio of rare disease, endocrinology, and musculoskeletal treatments in Switzerland.
EuRR
EuRREB – European Registries for Rare Endocrine and Bone conditions supports healthcare professionals, researchers, and patients in collecting data and proving collaborative research across Europe to improve the healthcare for patients with rare endocrine and bone diseases. EuRREB has two main platforms: e-REC and Core, which capture rare conditions covered within the reference networks ERN BOND and Endo-ERN. The registries are open to all professionals involved in the care of these conditions.
Gedeon Richter Plc
Gedeon Richter Plc. headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe (CEU), with an expanding global presence. The product portfolio of Richter covers Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in CEU, Richter’s original research activity focuses on CNS disorders. Richter is a significant player in the Women’s Healthcare field worldwide and is also active in biosimilar product development.
Inozyme Pharma, inc.
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established ENPP1 and ABCC6 genes play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies
KUBTEC Scientific
KUBTEC Scientific, a minority woman-owned company founded in 2005, headquartered in Stratford, Connecticut, is a progressive research and technology company dedicated to designing innovative and proprietary tools that include digital cabinet X-ray imaging and irradiator systems.
Our diverse range of applications includes life sciences imaging and irradiation for small animals and cells, agricultural and forestry sciences imaging, and other industrial applications developed for academic, government and industrial institutions.
Kyowa Kirin International Plc.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.
You can learn more about the business of Kyowa Kirin at:
https://international.kyowa-kirin.com/
*Harmony and loop among people.
REVVITY
We are immensely excited to share with you that we are Revvity, a visionary partner in developing technologies and solutions across disease pathways to help solve the world’s greatest health challenges.
The meaning behind Revvity
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents our commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere. We provide health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.
Your challenge is our call to action
We specialize in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Every day, our 11,000 employees worldwide collaborate to pioneer technologies, solutions, and services that help you, our customers, redefine the health of our world. With a robust global network and localized agility, we serve a diverse range of organizations from pharmaceutical and biotech, to clinical labs, academia, and governments.
Revvity exists to expand the boundaries of human potential through science. Together with our customers and partners we will bring our purpose to life.
Novotec Medical GmbH / Stratec Medizintechnik GmbH
Stratec Medizintechnik is the producer of pQCT-based bone densitometry scanners. Results are presented in real density units (g/cm³). Additionally, geometrical properties of bone can be analysed which allow the estimation of mechanical properties. The combined analysis of muscle and bone allows differentiation of disuse osteopenia from true osteoporosis.
The sister company Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). The side alternating technology employs a natural movement similar to human gait. Improvement of muscle function, treatment of back pain and immobility are typical fields of application.